US:
UK:
JAPAN:
- Report code : CMI-2815
- Industry : Medical Devices
- Published On : Jul 2019
- Pages : 178 Pages
- Format :
Press Release: PTA Balloon Catheter Market to Surpass US$ 2,038.6 Million by 2026
Press Release: PTA Balloon Catheter Market to Surpass US$ 2,038.6 Million by 2026
Global PTA Balloon Catheter Market
PTA stands for ‘percutaneous transluminal angioplasty’. PTA balloon catheter has an inflatable ‘balloon’ at its tip, which is used during a minimally invasive catheterization procedure. This procedure is used to enlarge the narrowed vessel opening. The deflated balloon is positioned at the narrowed space and inflated for the short period of time and deflated again to be removed. PTA balloons come in various sizes, lengths, and shapes, depending on the anatomy they are intended to treat. PTA balloon catheters can be used in two ways for the treatment of peripheral vascular lesions. One way is to expand the lumen of an obstructed blood vessel. This method is referred to as the ‘plain-old balloon angioplasty’ (POBA). The second use is for expanding stents for the treatment of vascular blockages.
The global PTA balloon catheter market size was valued at US$ 1,127.7 million in 2017, and is expected to exhibit a CAGR of 6.8% over the forecast period (2018 – 2026).
Figure 1. Global PTA Balloon Catheter Market Value (US$ Mn), by Region, 2018
Source: Coherent Market Insights Analysis (2018)
Increasing prevalence of urological and cardiovascular diseases is expected to propel the PTA balloon catheter market growth
Increasing prevalence of urological and cardiovascular diseases is expected to increase demand for PTA balloon catheters, which in turn is expected to fuel the PTA balloon catheter market growth over the forecast period. The urological diseases include, urinary tract infections, kidney stones, and prostate problems. According to, the American Cancer Society around 174,650 new cases and around 31,620 deaths occurs due to prostate cancer the U.S. in 2019. According to National Institute of Diabetes and Digestive and Kidney Diseases, in 2017, around 11% of men and 6% of women in the U.S. suffered from kidney stone.
Furthermore, according to the World Health Organization, cardiovascular diseases account for most of the non-communicable disease deaths. An estimated 17.9 million deaths were registered from cardiovascular diseases in 2016, representing 31% of the global deaths. Of these deaths, 85% were due to heart attack and stroke. Therefore, increasing prevalence of non-communicable diseases is expected to increase demand for catheters, which in turn is expected to drive growth of the PTA balloon catheter market over the forecast period.
Figure 2. Global PTA Balloon Catheter Market Share (%), by Material Type, 2018 and 2026
Source: Coherent Market Insights Analysis (2018)
Increasing Launch of New Products Is Expected To Boost the PTA Balloon Catheter Market Growth in North America
Major PTA balloon catheter manufacturers are focused on launching new products in North America to enhance their market share. For instance, in February 2016, Nipro North America, a division of Nipro Medical Corporation, announced the launch of Cronus HP high pressure, 0.035” over the wire (OTW) percutaneous transluminal angioplasty (PTA) balloon catheter. Cronus HP is indicated for percutaneous transluminal angioplasty in the femoral, popliteal, iliac, and renal arteries and for the treatment of obstructive lesions in native or synthetic arteriovenous dialysis fistulae.
Moreover, in February 2017, QT Vascular Ltd. signed an exclusive, worldwide distribution agreement with Medtronic to distribute the Chocolate PTA balloon catheter. It is currently available in the U.S. and Europe.
Furthermore, in May 2015, Direct Access Medical announced that it has received the U.S. Food and Drug Administration 510(k) clearance for the full line of FirstChoice ultra high pressure (UHP) percutaneous transluminal angioplasty (PTA) 0.035-inch over the wire balloon catheters.
Key Players
Major players operating in the global PTA balloon catheter market include, Medtronic, Terumo, Cardinal Health, Boston Scientific, AndraTec, Cook Medical, Biotronik, Abbott, Creagh Medical, TriReme Medical, and Natec Medical.
A catheter is a tubular, flexible instrument, passed through body channels for withdrawals of fluid (or introduction of fluids) from body cavity. PTA balloon catheter is an innovative medical device, which is inserted in the femoral artery in the leg or sometimes into the radial artery in the arm for the treatment of constricted blood vessels. The PTA means “percutaneous transluminal angioplasty” (percutaneous means through the skin). As the balloon inflates, the cage causes the balloon to form a series of segmented pillows and grooves along the entire lesion. The pillows apply force to create small dissections that are necessary for effective dilatation. The grooves relieve the stress and stop dissections from propagating. The PTA balloon catheters is used in for the treatment of peripheral vascular lesions. The standard PTA balloon catheter segment has represented the largest share of the total PTA balloon catheter market. However, Boston ScientificÂs exit from the standard PTA balloon catheter space in 2014 reduced the size of the market in that year. The value of the high-pressure PTA balloon catheter market increased sharply in 2014 as Boston Scientific shifted resources from the standard to high-pressure PTA balloon catheter markets.
Market Dynamics
Increasing prevalence of urological and cardiovascular diseases, geographical expansion of PTA balloons catheter manufacturers in North America, and increasing investment in research and development by manufacturers are some of the major factors that are expected to drive the market growth. Furthermore, increasing production of PTA balloon catheter is expected to driving growth of global PTA balloon catheter market. For instance, in April 2015, BrosMed announced CE mark and launched its Minerva percutaneous transluminal angioplasty (PTA) dilation catheter for the treatment of patients with peripheral arterial disease.
Moreover, in April 2018, the Metronic, Inc IN.PACT Admiral Paclitaxel-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter received the U.S. FDA approval. The Medtronic IN.PACT Admiral Paclitaxel-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Medtronic DCB) uses a drug-coated balloon to re-open blocked or narrowed arteries in the thigh and knee due to peripheral artery disease (PAD).
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 32 market data tables and 20 figures on "PTA Balloon Catheter Market - Global forecast to 2026”.
Asia Pacific Intelligence Center (India): 